How to approach a child with growth concern
|
|
- Bridget Logan
- 6 years ago
- Views:
Transcription
1 How to approach a child with growth concern Alaa Al Nofal, MD Assistant Professor of Pediatrics Pediatric Endocrinology Sanford Children Specialty Clinic
2 Nothing to disclose Disclosure
3 Objectives To understand the normal patterns of growth throughout childhood When to get concerned about the child s height How to evaluate a child with short stature? Management of short stature
4 When do children have the fastest rate of growth? 1) First year of life 2) Second year of life 3) Third year of life 4) 4 years-puberty 5) Puberty
5 When do children have the fastest rate of growth? 1) First year of life 2) Second year of life 3) Third year of life 4) 4 years-puberty 5) Puberty 25 cm/year 12 cm/year 8-10 cm/year 5-7 cm/year 8 cm/year for girls 10 cm/year of boys
6 Growth Velocity
7 14 year old girl, who is new to your practice, is coming to the clinic for a regular annual checkup Patient and her family have no concerns today Family reports patient has been growing along the 10 th percentile Patient has just had menarche
8 What is the next step in management: 1. Karyotype 2. Check TSH 3. Bone age 4. Bone age, TSH, FT4, IGF1, IGFBP3, MRI brain and referral to endocrinology 5. Plot her height on a CDC growth chart for girls
9 10 year old boy is coming to the clinic for a regular annual checkup He was seen by you 2 months ago for strep throat Patient and his family have no concerns today Patient has no signs of puberty on exam
10 What is the next step in management: 1. Dietician consult 2. Check TSH 3. Bone age 4. Bone age, TSH, FT4, IGF1, IGFBP3, brain MRI and referral to endocrinology 5. Recheck the child s height
11 Accurate height or length measurements are essential Inaccurate measurement or graph plotting is one of the more common causes of apparent growth failure
12 Measuring length and height Length: Used for children younger than 2 years of age When measured, the length should be plotted on the WHO growth chart for length At any age, measurement of length is approximately 1 cm greater than measurement of height
13 Measuring length and height Height: Height measurement is recommended for children over 2 years of life if possible When measured, the height should be plotted on the CDC growth chart for height
14 Measuring length and height Length: Recumbent position using calibrated lengthboard Fixed headpiece and movable footpiece Infant should be wearing disposable diaper with/without undershirt
15 Measuring length and height Height Movable head projection Hats/hair ornaments removed Head in line with head plate Horizontal axis of vision Measurer applies gentle traction beneath the jaw to maintain position Fixed measuring device attached to a wall Head, shoulders, buttocks and heels in contact with the vertical surface Shoes off Heels together
16 A 9 month old infant who was born to a diabetic mother is brought to the clinic for a well child checkup He has a history of transient hypoglycemia after birth Birth weight and birth length were both on the 90 th percentile He is currently on the 50 th percentile for length and 60 th percentile for weight He is healthy otherwise
17 What is the next step in management: 1. Dietician consult 2. Check TSH 3. Bone age 4. Bone age, TSH, FT4, IGF1, IGFBP3, MRI brain, abdominal US and referral to endocrinology 5. None of the above
18 It can be normal for young infants 0-6 months of age to cross percentiles on the weight or length curve Up to two-thirds of the infants at this age group are likely to cross 2 major weight for length percentiles Mei Z et al, Pediatrics. June 2004;113(6):e617-e627. Al Nofal A et all, Nut Clin Pract. Dec 2013 ;28(6):651-8
19 11 year old boy is new to your practice, coming for a well child checkup Mother reports that he has not been growing well He feels fine Past medical history is unremarkable Patient is pre-pubertal
20 What is the next step in management: 1. Dietician consult 2. Check TSH 3. Reassurance 4. MRI brain
21 Growth velocity is a more sensitive index of growth than is a single measurement Current growth measurements should be compared to previous growth measurements to determine the interval growth velocity
22 5 year old girl is coming with concern about short stature She has no symptoms Patient is pre-pubertal
23
24 Mother is 5 8 and father is 6 3
25 Mid-parental height/target height Girls: Father s height + Mother s height 13 cm (5 in) 2 Boys: Father s height + Mother s height + 13 cm (5 in) 2
26 Mid-parental height/target height Our patient s mid-parental height: ( )/2 =69
27 What is the next step in management: 1. Dietician consult 2. Reassurance 3. Bone age 4. Follow up in 1 year Predicted midparental height
28 Assuming father s height is 5 7 and mother s height is 5 feet tall Mid-parental height: ( )/2 = 61 inches (5 1) What is the next step in management: 1. Dietician consult 2. Reassurance 3. Bone age 4. Follow up in 6 month Predicted mid-parental height
29 Projected height Projected height for a child is determined by extrapolating the child's growth along the current channel to the 18 to 20 year mark If the child s projected height is within 8.5 cm (3-4 inches) of the midparental height, then the child's height is within the expected range for the family If the projected height is more than 8.5 cm below the midparental height, then the child can be considered abnormally short for his or her family
30 14 year old boy is coming to the clinic today for concerns about short stature He used to be following the 25 th percentile on the height s growth chart until 11 years of age, but currently he is on the 5 th percentile Otherwise he is a healthy boy No signs of puberty Case presentation
31 What is the next step in management: 1. Dietician consult 2. Check TSH 3. Bone age 4. Bone age, TSH, FT4, IGF1, IGFBP3, MRI brain, abdominal US and referral to endocrinology 5. Insulin like growth factor 1 (IGF1) level
32 Teenagers with constitutional delay may appear to be crossing percentiles Bone age: Determined from a radiograph of the left hand and wrist Requires expert interpretations If the bone age is delayed or advanced, the projected height should be recalculated based on the bone age rather than the chronologic age Al Nofal A et all, Nut Clin Pract. Dec 2013 ;28(6):651-8
33 10 year old girl is coming to the clinic for a regular checkup Family is concerned about her growth She is a picky eater No signs of puberty
34 What is the next step in management: 1. Endocrine referral 2. Reassurance 3. Bone age 4. Detailed diet history, medications list and GI symptoms 5. Follow up in 1 year
35 10 year old girl is coming to the clinic for a regular checkup Family is concerned about her growth She eats well No signs of puberty
36
37 What is the next step in management: 1. Endocrine workup 2. Reassurance 3. GI referral 4. Detailed diet history, medications list and GI symptoms 5. Follow up in 3 months
38 A pediatric endocrinologist is checking his patients schedule for next week A patient is scheduled to see him for obesity No outside records available except for a growth chart
39 The most likely cause of this patient s obesity is: 1. Severe hypothyroidism 2. Cushing disease 3. Genetic cause of obesity (Prader Willi syndrome) 4. Exogenous obesity
40 A pediatric endocrinologist is checking his patients schedule for next week A patient is scheduled to see him for obesity No outside records available except for a growth chart
41 The most likely cause of this patient s obesity is: 1. Cushing disease 2. Genetic cause of obesity (Prader Willi syndrome) 3. Exogenous obesity 4. Normal weight gain with start of puberty
42 3 year old child is brought to the clinic for concerns about obesity Past medical history is significant for hypotonia and feeding difficulty during infancy, for which he required G-tube Family now hides food from the child because he never seems to be full Patient has small hands and small feet
43 The most likely cause of this patient s obesity is: 1. Cushing disease 2. Genetic cause of obesity (Prader Willi syndrome) 3. Exogenous obesity 4. Normal weight gain
44 Short stature workup Before starting workup for patients with growth concerns, the following questions need to be answered: 1. Is the child short? 2. Is the child s height velocity impaired? 3. Is the child s growth within range for the family? 4. Is the child in puberty? (Is there evidence of delayed or accelerated growth?)
45 Differential diagnosis for short stature Short child + Normal rate of growth + short family + normal bone age Familial short stature Short child for his family + Normal rate of growth + delayed bone age Short child for his family + subnormal rate of growth + normal bone age Short child for his family + subnormal rate of growth + delayed bone age + normal weight gain Short child for his family + subnormal rate of growth + delayed bone age + poor weight gain Constitutional delay of growth and puberty Genetic cause of short stature (e.g. Turner s, Noonan Syndrome) Endocrine cause or systemic disease cause of short stature GI cause or systemic disease cause for short stature
46 Short stature workup Bone age CBC, CMP, ESR, CRP Celiac screen Thyroid function IGF1, IGFBP3 Growth hormone stimulation test Brain MRI Genetic testing
47 FDA approved indications for growth hormone Growth hormone deficiency Growth failure due to chronic kidney disease Growth failure in children born small for gestational age Prader-Willi syndrome in children Turner s syndrome Noonan syndrome Idiopathic short stature Short stature due to homeobox containing gene deficiency
48 Growth hormone adverse effects In addition to being a daily injections (or 6 days a week): Headaches usually benign Idiopathic intracranial hypertension Slipped capital femoral epiphysis Worsening of existing scoliosis Insulin resistance (low clinical significance) Rare adverse effects: Pancreatitis, transient gynecomastia, increase in the growth and pigmentation of nevi without malignant degeneration, etc? Cancer risk Cost!
49 Take home points When evaluating a child s height, it s crucial to accurately measure and plot the child s height The following information are needed when evaluating a child with growth concern: Current height Growth velocity Mid-parental height Pubertal stage Bone age is a tool that helps estimate the projected height Not every short child can be treated with growth hormone
50 Thank you Questions?
PedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Approach to Pediatric Anemia and Pallor. These podcasts are designed to give medical students an overview of key
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More information4/23/2015. Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management. Conflict of Interest. Objectives THANK YOU!
Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management Kent Reifschneider, MD CHKD / EVMS Norfolk, VA Conflict of Interest Speaker bureau and advisor for Pfizer Board member of The
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, Zomacton (aka. Tev-Tropin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.12 Subject: Growth Hormone Pediatric Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More information2. Is the request for Humatrope? Y N [If no, skip to question 6.]
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Growth Hormone Agents This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationGrowth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮
Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000
More informationGrowth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka
Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First
More informationPrior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products
Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name:
More informationGeneral Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)
Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred
More informationOriginal Effective Date: 7/5/2007
Subject: Recombinant Human Growth Hormone: PEDIATRIC_GENETIC DISEASES with Primary Effects on Growth Turner syndrome Noonan syndrome Prader-Willi syndrome SHOX mutations DISCLAIMER Original Effective Date:
More informationWhy is my body not changing? Conflicts of interest. Overview 11/9/2015. None
Why is my body not changing? Murthy Korada Pediatrician, Pediatric Endocrinologist Ridge Meadows Hospital Surrey Memorial Hospital None Conflicts of interest Overview Overview of normal pubertal timing
More informationLinear Growth Assessment: Evaluation and Causes and Treatment of Growth Failure
Linear Growth Assessment: Evaluation and Causes and Treatment of Growth Failure Terri H. Lipman PhD, CRNP, FAAN University of Pennsylvania, School of Nursing Children s Hospital of Philadelphia Growth
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationGrowth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5
Disorders of Growth and Puberty: How to Recognize the Normal Variants vs Patients Who Need to be Evaluated Paul Kaplowitz, M.D Pediatric Endocrinology. VCU School of Medicine Interpretation of Growth Charts
More informationGrowth Hormones DRUG.00009
Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved
More informationThis CNE activity is supported by an educational grant from Novo Nordisk Inc.
This CNE activity is supported by an educational grant from Novo Nordisk Inc. Objectives Differentiate between normal growth variants and growth variants that are linked to a disorder Describe the process
More informationGrowth and DMD Endocrine aspects of care
Growth and DMD Endocrine aspects of care Meilan Rutter, MB,BCh, FRACP Division of Endocrinology Cincinnati Children s Hospital Medical Center July 2007 Where are we now? Inactive Reactive Proactive CCHMC
More informationObesity in Children. JC Opperman
Obesity in Children JC Opperman Definition The child too heavy for height or length Obvious on inspection 10 to 20% over desirable weight = overweight More than 20% = obese Use percentile charts for the
More informationThe University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Endocrinology
The University of Arizona Pediatric Residency Program Primary Goals for Rotation Endocrinology 1. GOAL: Understand the role of the pediatrician in preventing endocrine dysfunction, and in counseling and
More informationInstructor s Manual Chapter 28 Endocrine Alterations. 1. Which of the following is an example of a negative feedback system?
1 Instructor s Manual Chapter 28 Endocrine Alterations Answers to Study Questions 1. Which of the following is an example of a negative feedback system? a. Hypothalamus secretes ACTH, stimulating the anterior
More informationElements for a Public Summary
Page 3 of 7 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Growth hormone deficiency occurs when the pituitary gland does not produce enough growth hormone.. Growth hormone
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including
More informationGROWTH HORMONE THERAPY
GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationEndocrine: Precocious Puberty Health care guidelines for Spina Bifida
Endocrine: Precocious Puberty Health care guidelines for Spina Bifida Precocious Puberty Primary outcome: Timely assessment, identification, appropriate referral, and management of precocious puberty.
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationOn the go. with Norditropin. Patient travel tips
On the go with Norditropin Patient travel tips Indications and Usage: What is Norditropin (somatropin [rdna origin] injection)? Norditropin is a prescription medicine that contains human growth hormone
More informationGrowth and Puberty: A clinical approach. Dr Esko Wiltshire
Growth and Puberty: A clinical approach Dr Esko Wiltshire NOTHING TO DISCLOSE Why is this character short? Food Psychosocial factors Major Systems (+drugs) Genetic potential Perinatal Classical Hormones
More informationRenee Kinman, MD PhD
Renee Kinman, MD PhD 9 y/o girl Referred by PMD for short stature Fell off growth chart Idiopathic Familial Genetic causes/ Turner syndrome Chronic Disease Constitutional Delay Growth Hormone Deficiency
More informationCIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -
Pharmacy Services Phone: (800)244-6224 Fax: (800)390-9745 CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Notice: Failure to complete this form in its entirety may result in delayed
More informationProvide preventive counseling to parents and patients with specific endocrine conditions about:
Endocrinology Description: The resident will become familiar with the diagnosis, management, and treatment of endocrine problems. The resident will evaluate patients with a multitude of endocrine problems,
More informationAetna Better Health of Virginia
Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration
More informationThe science behind igro
The science behind igro igro is an interactive tool that can help physicians evaluate growth outcomes in patients receiving growth hormone (GH) treatment. These pages provide an overview of the concepts
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SOMATROPIN HUMATROPE GENOTROPIN NORDITROPIN NORDITROPIN FLEXPRO NORDITROPIN NORDIFLEX NUTROPIN NUTROPIN AQ OMNITROPE SAIZEN ZOMACTON 02824 BRAND ZORBTIVE BRAND SEROSTIM
More informationChildren s Hospital & Research Center Oakland. Endocrinology
Children s Hospital & Research Center Oakland Endocrinology 5.22 GOAL: Prevention, Counseling and Screening (Endocrine). Understand the role of the pediatrician in preventing endocrine PC, MK, dysfunction,
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Norditropin (somatropin)
More informationCircle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]
05/20/2015 Prior Authorization MERC CARE PLA (MEDICAID) Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationDiagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health
Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological
More informationGrowth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives
At a Glance Review Article Practical Implications e135 Author Information e144 Full text and PDF Growth Hormone Therapy Guidelines: Clinical and Managed Care Perspectives Susan R. Rose, MD; David M. Cook,
More informationGrowth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit
Sotos and Tokar International Journal of Pediatric Endocrinology 2014, 2014:15 RESEARCH Open Access Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison
More informationGenotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen,
Blue Cross Blue Shield of Vermont and The Vermont Health Plan Prior Approval Guidelines Human Growth Hormone Somatropin (Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Serostim, Saizen, Zomacton/TevTropin,
More informationAETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents
AETNA BETTER HEALTH Prior Authorization guideline for Growth Hormone Agents Growth Hormone and related agents Formulary: Omnitrope vials Non-Formulary: Genotropin, Humatrope, Saizen, Serostim, Tev-Tropin,
More informationGROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT
1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy
More informationPHARMACY POLICY STATEMENT Indiana Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Zomacton (somatropin) Must
More informationNOVO NORDISK A/S. 3. Pharmacotherapeutic group Somatropin is an endocrine hormone with metabolic and growth promoting effects. 4.
08-15 Norditropin NordiLet 10 mg/1.5 ml NOVO NORDISK A/S 1. Name of the medicinal product Norditropin NordiLet 10 mg/1.5 ml Pre-filled pen, solution for injection 2. Composition Norditropin NordiLet is
More informationPREP Pediatric Endocrinology General session. Srinath Sanda, M.D. UC San Francisco
PREP 2017 Pediatric Endocrinology General session Srinath Sanda, M.D. UC San Francisco Disclosures o I have no relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Human Growth Hormone Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2018 P 1039-8 Program UnitedHealthcare Pharmacy Clinical Pharmacy Programs Prior Authorization/Notification Human Growth Hormone, Growth Stimulating Products Medication Human Growth Hormone:
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2016-8 Program Prior Authorization/Medical Necessity Medication Human Growth Hormone: Somatropin (Genotropin *, Humatrope *, Norditropin
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Human Growth Hormone Page 1 of 44 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s
More informationClinical Policy: Somatropin (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17
Clinical Policy: (Recombinant Human Growth Hormone) Reference Number: CP.PHAR.55 Effective Date: 03/11 Last Review Date: 06/17 Line of Business: Medicaid Revision Log See Important Reminder at the end
More informationHyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea
Clin Pediatr Endocrinol 1996; 5(2), 61-66 Copyright (C) 1996 by The Japanese Society for Pediatric Endocrinology Hyperprolactinemia in A 15-Year-Old Girl with Primary Amenorrhea Toshihisa Okada, Soroku
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti-Doping Agency International Standard for TUEs. The TUE application process
More informationGROWTH ASSESSMENT AND GROWTH DISORDERS. IAP UG Teaching slides
GROWTH ASSESSMENT AND GROWTH DISORDERS 1 GROWTH PARAMETERS TO BE MONITORED Birth 2 years: Weight, length & head circumference at birth, immunization contacts at 6, 10, 14 weeks, 9 months, 15 months & 18
More informationGH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK
GH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK Overview GH therapy Indications Specific advantages Extra precautions Case scenarios without
More informationPharmacy Prior Authorization Growth Hormone- Clinical Guidelines
Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Serostim, somatropin, Zorbtive, Zomacton I. Growth Hormone Deficiency in Children and Adolescents: Note: Provider must submit chart notes
More informationDISCLOSURES: 8/27/18 USE OF A SHARED MEDICAL APPOINTMENT FOR PEDIATRIC OBESITY
DISCLOSURES: Nothing to disclose USE OF A SHARED MEDICAL APPOINTMENT FOR PEDIATRIC OBESITY Catherine Lux, DNP,RN,CPNP-PC https://encrypted-tbn0.gstatic.com/images?q=tbn:and9gcrafxzs7e6tfxm2vxdjdp9fmkun25ryuuyqimh2f4zgg2df_gs_sq
More informationSCRIPT: Module 3. Interpreting the WHO Growth Charts for Canada SLIDE NUMBER SLIDE SCRIPT
SCRIPT: Module 3 Interpreting the WHO Growth Charts for Canada 1 Welcome Welcome to Module 3 - Interpreting the WHO Growth Charts for Canada. Each of the modules in this training package has been designed
More informationHUMAN GROWTH HORMONE GENOTROPIN
Drug Prior Authorization Guideline HUMAN GROWTH HORMONE GENOTROPIN (somatropin) PA9728 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes Additional Information: Medicare
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (somatropin) injection, for subcutaneous
More informationKlinefelter syndrome ( 47, XXY )
Sex Chromosome Abnormalities, Sex Chromosome Aneuploidy It has been estimated that, overall, approximately one in 400 infants have some form of sex chromosome aneuploidy. A thorough discussion of sex chromosomes
More informationPRODUCT MONOGRAPH. Pr HUMATROPE. (somatropin for injection) Biosynthetic Human Growth Hormone of Recombinant DNA Origin
PRODUCT MONOGRAPH Pr HUMATROPE (somatropin for injection) Biosynthetic Human Growth Hormone of Recombinant DNA Origin 5 mg vial 6, 12, 24 mg cartridges Sterile Lyophilized Powder and Diluent Lilly Standard
More informationROTATION SUMMARY ENDOCRINOLOGY
ROTATION SUMMARY ENDOCRINOLOGY Rotation Contacts and Scheduling Details Rotation Director: Caroline Buckway, MD cbuckway@stanford.edu 650-721-1811 G313, SUMC Administrator: Ofelia Colin ofeliag@stanford.edu
More informationObjectives. Disclosures
Klinefelter Syndrome: A Near Miss in a Child with Congenital Hypothyroidism Mandi Cafasso, RN, DNP, CPNP Cincinnati Children s Hospital Medical Center April 28, 2017 Minneapolis, MN PENS Conference Objectives
More informationPFIZER INC. PROTOCOL TITLE: Efficacy and Safety of the Authentic Recombinant Human Somatropin Genotropin in Children with Familial Short Stature
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationEndocrine. Joe O Neil, MD, Chair
Endocrine Joe O Neil, MD, Chair Definitions Endocrine Section is comprised of 3 parts: Precocious Puberty Short Stature and Effect of Growth Hormone Obesity Puberty Definitions Puberty is defined as presence
More informationGrowth Hormone!gents. WA.PHAR.50 Growth Hormone Agents
Growth Hormone!gents WA.PHAR.50 Growth Hormone Agents Background: Human growth hormone, also known as somatotropin, is produced in the anterior lobe of the pituitary gland. This hormone plays an important
More informationDR. SHAHJADA SELIM. Growth Hormone Deficiency. Subdivisions of Growth Hormone Deficiency. General Discussion. Signs & Symptoms
Growth Hormone Deficiency NORD gratefully acknowledges Joe Head, NORD Intern and Richard A. Levy, MD, Director of Pediatric Endocrinology Section, Rush University, for their assistance in the preparation
More informationLaura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia
Precocious Puberty Laura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia Faculty Disclosure Faculty: Laura Stewart No relationships with
More informationHypothalamic & Pituitary Hormones
1 Hypothalamic & Pituitary Hormones Pharmacologic Applications: Drugs that mimic or block the effects of hypothalamic or pituitary hormones have the following applications: 1. Replacement therapy for hormone
More informationNorditropin SimpleXx 5 mg/1.5 ml One ml of solution contains 3.3 mg somatropin (GROWTH HORMONE HUMAN BIOSYNTHETIC)
פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר על ידו בפברואר 3102 1. NAME OF THE MEDICINAL PRODUCT Norditropin SimpleXx 5 mg Norditropin SimpleXx 10 mg Norditropin SimpleXx 15 mg Solution for injection
More information0.33% metacresol), with a vial adapter
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZOMACTON safely and effectively. See full prescribing information for ZOMACTON. ZOMACTON (somatropin)
More informationThe Stimulation Test. What, Why, and How. Date. Time. Place. Dr./Nurse. Phone _elhmtp_HG64712_stim_br_fa3.indd 3
The Stimulation Test Date Time Place Dr./Nurse Phone 45364_elhmtp_HG64712_stim_br_fa3.indd 3 7/28/10 1:46:55 PM What You Should Know About Your Child s Stimulation Test 2 Key Terms 3 Normal Growth 4 Evaluation
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 8, 2017 Growth Hormone Adult
More informationWorld Health Organization Growth Standards. BC Training Module PowerPoint Speaking Notes
World Health Organization Growth Standards BC Training Module PowerPoint Speaking Notes May 30, 2011 British Columbia WHO Growth Chart Training June 2011 Page 1 PowerPoint Speaking Notes Slide 1 Title
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: September 15, 2016 Growth Hormone
More informationPediatric Gastroenterology Referral Guidelines
Suggested Pre-Referral Workup This is a general suggestion of possible testing to confirm a suspected diagnosis. Although referrals will be accepted without the suggested work up being complete, to ensure
More informationStatement of Medical Necessity
Y E A R S (somatropin [rdna origin] for injection) Statement of Medical Necessity See inside cover for a list of documentation to accompany the Omnitrope Statement of Medical Necessity (SMN). Documentation
More informationExpert Committee Recommendations on the Assessment, Prevention and Treatment of Child and Adolescent Overweight and Obesity
Expert Committee Recommendations on the Assessment, and Treatment of Child and Adolescent Over and Obesity - 2007 - An Implementation Guide from the Childhood Obesity Action Network - Overview: In 2005,
More informationCase Report Short Stature Homeobox-Containing Haploinsufficiency in Seven Siblings with Short Stature
Hindawi Case Reports in Endocrinology Volume 2017, Article ID 7287351, 5 pages https://doi.org/10.1155/2017/7287351 Case Report Short Stature Homeobox-Containing Haploinsufficiency in Seven Siblings with
More informationPuberty and Pubertal Disorders Part 3: Delayed Puberty
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Puberty and Pubertal Disorders Part 3: Delayed Puberty These podcasts are designed to give medical students an overview
More informationPharmacy Management Drug Policy
SUBJECT: Policy POLICY NUMBER: Pharmacy-18 EFFECTIVE DATE: 08/03 LAST REVIEW DATE: 9/24/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not
More informationA Crash Course in Failure to Thrive April 5, Kelly E. Wood, MD Clinical Assistant Professor Stead Family Department of Pediatrics
A Crash Course in Failure to Thrive April 5, 2016 Kelly E. Wood, MD Clinical Assistant Professor Stead Family Department of Pediatrics Disclosures I have nothing to disclose Educational Objectives Define
More informationGrowth disorders in adolescents
FOCUS Growth disorders in adolescents Tashunka Taylor-Miller, Peter J Simm Background Growth is one of the fundamental processes of adolescent development. Careful history and examination, and relevant
More informationFalling Off the Curve Failure to Thrive
Falling Off the Curve Failure to Thrive Robert Rothbaum, MD Friday, November 4 8:00 8:45 am Dr. Robert Rothbaum is Centennial Professor of Pediatrics and clinical director of the Division of Pediatric
More informationMEDICAL POLICY I. POLICY HUMAN GROWTH HORMONE MP POLICY TITLE POLICY NUMBER
g Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 I. POLICY Recombinant human growth hormone (GH) therapy may be considered medically
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. GROWTH HORMONE THERAPY POLICY Omnitrope is the EXCLUSIVE growth hormone covered if patient meets criteria. COVERAGE
More informationCenter for healthy weight and Nutrition. Primary Care Pocket Guide to. Pediatric Obesity Management
Center for healthy weight and Nutrition Primary Care Pocket Guide to Pediatric Obesity Management Introduction The Primary Care Pocket Guide to Pediatric Obesity Management is intended to provide primary
More informationNorditropin Cartridges [somatropin (rdna origin) injection], for subcutaneous use Initial U.S. Approval: 1987
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all of the information needed to use Norditropin Cartridges safely and effectively. See full prescribing information for Norditropin
More informationSHORT STATURE Growth Height Measurement
SHORT STATURE Pages with reference to book, From 217 To 219 A. H. HAQUANI ( National Institute of Child Health, Jinnah Postgraduate Medical Centre, Karachi. ) The purpose of this communication is to draw
More informationTimothy Fignar, MD FAAFP
Timothy Fignar, MD FAAFP Council for Obesity Related Education (CORE) speakers bureau for Takeda Pharmaceuticals Evaluate Health Risks Adjust Current Medications Recommend Caloric Intake Build Safe Exercise
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Puberty and Pubertal Disorders Part 2: Precocious Puberty. These podcasts are designed to give medical students an overview
More informationClinical Standards for GH Treatment in Childhood & Adolescence.
Clinical Standards for GH Treatment in Childhood & Adolescence. The Clinical Standards for GH treatment have been produced by the Clinical Committee of the BSPED. They are evidence based where possible
More informationHumatrope*, Norditropin*, Genotropin, Nutropin, Nutropin AQ, Omnitrope, Saizen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.11 Subject: Growth Hormone Adult Page: 1 of 6 Last Review Date: December 5, 2014 Growth Hormone Adult
More information